Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Q: How do the newly granted Praxis (PRAX) restricted stock units vest for employees?

The newly granted Praxis RSUs vest in four equal annual installments . According to Praxis, vesting is contingent on each recipient’s continued employment with the company on the applicable vesting dates, aligning equity incentives with long-term service.

Q: Why did Praxis Precision Medicines (PRAX) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?

Praxis used Nasdaq Listing Rule 5635(c)(4) because the RSUs are inducement awards tied to new employment. According to Praxis, this rule allows equity grants as material inducements for new hires outside existing shareholder-approved plans.

Q: How many employees received Praxis (PRAX) inducement RSUs and in what roles?

Praxis granted inducement RSUs to 29 new non-executive employees . According to Praxis, all recipients are non-executive hires, reflecting the company’s use of equity-based incentives to attract and retain staff under its 2024 Inducement Plan.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) reported that on August 3, 2026, its Board Compensation Committee granted restricted stock unit (RSU) awards covering an aggregate of 7,318 common shares to 29 new non-executive employees under the 2024 Inducement Plan. According to Praxis, these RSUs were approved as employment inducement grants in line with Nasdaq Listing Rule 5635(c)(4) and are reserved for individuals not previously employed by the company, or rehired after a bona fide break in service. The RSUs will vest in four equal annual installments, contingent on each employee’s continued employment with Praxis on the applicable vesting dates.

Market Context

Recent insider activity was labeled Net Selling, with 0 shares bought and 9,597 sold. That context a...

Analysis

Recent insider activity was labeled Net Selling, with 0 shares bought and 9,597 sold. That context adds a governance lens to the awards; the four-installment vesting schedule makes employee retention the stated condition to watch.

Key Figures

Shares granted: 7,318 shares Recipients: 29 employees Vesting schedule: 4 equal annual installments +2 more

5 metrics

Shares granted 7,318 shares Restricted stock units granted on August 3, 2026

Recipients 29 employees New non-executive employees

Vesting schedule 4 equal annual installments Subject to continued employment on each vesting date

Listing rule Nasdaq Listing Rule 5635(c)(4) Inducement grants

Plan year 2024 2024 Inducement Plan

Historical Context

5 past events · Latest: Jul 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Strategic collaboration	Positive	+3.3%	Transdermal ulixacaltamide collaboration and equity investment in Remagine Labs
Jul 02	Inducement grants	Neutral	-1.6%	Restricted stock units granted to five new non-executive employees
Jun 29	FDA review extension	Negative	-4.5%	Relutrigine PDUFA date moved three months after major amendment
Jun 22	Breakthrough designation	Positive	+7.5%	FDA designation followed EMBRAVE results showing 77% seizure reduction
Jun 04	Healthcare conference	Neutral	-4.1%	Corporate overview scheduled for Goldman Sachs healthcare conference

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive partnership and clinical-designation news had positive reactions, while the comparable inducement-grant announcement was followed by a negative reaction.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4)

2 terms

restricted stock units financial

"granted restricted stock unit awards covering an aggregate of 7,318 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/04/2026 - 04:01 PM

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on August 3, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 7,318 shares of its common stock to twenty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What inducement equity grants did Praxis Precision Medicines (PRAX) announce on August 4, 2026?

Praxis Precision Medicines announced RSU awards for an aggregate of 7,318 shares of common stock to 29 new non-executive employees. According to Praxis, these awards were granted on August 3, 2026 under its 2024 Inducement Plan.

Who is eligible for the Praxis Precision Medicines 2024 Inducement Plan (PRAX)?

The 2024 Inducement Plan is used exclusively for individuals who were not previously Praxis employees, or are rehired after a bona fide non-employment period. According to Praxis, equity awards under this plan serve as material inducements for entering employment.

How do the newly granted Praxis (PRAX) restricted stock units vest for employees?

The newly granted Praxis RSUs vest in four equal annual installments. According to Praxis, vesting is contingent on each recipient’s continued employment with the company on the applicable vesting dates, aligning equity incentives with long-term service.

Why did Praxis Precision Medicines (PRAX) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?

Praxis used Nasdaq Listing Rule 5635(c)(4) because the RSUs are inducement awards tied to new employment. According to Praxis, this rule allows equity grants as material inducements for new hires outside existing shareholder-approved plans.

How many employees received Praxis (PRAX) inducement RSUs and in what roles?

Praxis granted inducement RSUs to 29 new non-executive employees. According to Praxis, all recipients are non-executive hires, reflecting the company’s use of equity-based incentives to attract and retain staff under its 2024 Inducement Plan.